Sponsor
National Cancer Institute (NCI)
Status
Not yet recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05521698
This phase I trial evaluates the effects of apalutamide, compared to placebo, on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.
Intervention
Apalutamide, Biopsy, Biospecimen Collection, Placebo Administration, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Condition
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Investigators
Edward M Messing, Kyle A. Richards, Michael A. Ahdoot, Juan Chipollini, Sandeep Gurram, Debasish Sundi